Tony Berberabe, MPH

Articles

Swedish Biomarker Test STHLM3 Identifies Aggressive Form of Prostate Cancer

November 26th 2015

A test called the Stockholm 3 (STHLM3) has been shown to detect aggressive prostate cancer cancer earlier, reduce the number of false positives, and decrease the number of unnecessary biopsies.

Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM

November 21st 2015

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

Physician Dispensing of Abiraterone and Enzalutamide for mCRPC Gains Appeal

November 7th 2015

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

Novel Combinations Hold Promise in Treatment-Resistant mCRPC

November 6th 2015

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

LUGPA Meeting Focuses on Business and Clinical Challenges

November 4th 2015

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

Enhanced Immune Response Seen With Radiation/Ipilimumab Combo in Melanoma

October 24th 2015

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic antiâ€“CTLA-4 immunotherapy, ipilimumab.

High-Intensity Ultrasound Device for Prostate Surgery Clears FDA Hurdle

October 13th 2015

The FDA has issued a de novo clearance for a minimally invasive high-intensity focused ultrasound for prostate tissue ablation called Sonablate 450 and marketed by SonaCare Medical, LLC.

In Kidney Cancer, Better Outcomes Demonstrated With Nephron-sparing Surgery

October 12th 2015

Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.

One Clinic's Multidisciplinary Approach Optimizes the Use of Radium-223

September 20th 2015

With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.

Start Discussions About Palliative Care Upon Initial Metastatic Diagnosis

August 11th 2015

In the urologic oncology field, urologists can play an important role in successful comprehensive care by incorporating palliative care in their treatment regimens.

Early Docetaxel, ADT Combo Increases Survival in Advanced Prostate Cancer

August 10th 2015

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

New Diagnoses of Prostate Cancer Decline Nearly 30% Following USPSTF PSA Decision

August 6th 2015

New diagnoses of prostate cancer cases declined nearly 30% after the United States Preventive Services Task Force recommended against routine prostate-specific antigen screening for men.

Study Says Urologists in Solo Practice May Overuse Gonadotropin Agonists

August 5th 2015

Urologists who are in solo practice or not affiliated with a medical school may overuse primary gonadotropin-releasing hormone for men with localized prostate cancer.

Men With Intermediate or High-Risk Prostate Cancer See Survival Benefit From Increased Radiation Therapy

August 4th 2015

Men with intermediate- or high-risk prostate cancer experienced higher survival rates when given increased radiation doses than men with low-risk disease.

Concurrent Statin Use in ADT Patients Reduced All Cause, Prostate Cancer-Specific Deaths

July 29th 2015

Patients who were taking statins while also undergoing androgen deprivation therapy may experience a reduction in all-cause and prostate cancer-specific deaths.

Improved Survival Data Seen With Abiraterone as COUGAR Trial Concludes

July 27th 2015

Charles J. Ryan, MD, discusses the final survival data for pre-chemotherapy use of abiraterone from the COUGAR-AA-302 study, which demonstrated a median of 35 months for men with castration resistant prostate cancer.

Specialty Pharmacy Makes Inroads in Urology Practice

June 10th 2015

There are many processes for a urology practice to consider when partnering with a specialty pharmacy, including time and capital investments.

Amnion/Chorion Wrap Improves Outcomes Following Robot-Assisted Prostatectomy

June 7th 2015

Using an allograft made up of dehydrated human amnion/chorion membrane wrapped around the neurovascular bundle (NVB) during nerve-sparing robot-assisted radical prostatectomy improved continence and potency postsurgery, according to results of a small study.

Progress in Immunotherapy Continues, But Pseudo-Progression Is a Concern

June 5th 2015

Interest is high among urologists and medical oncologists with "the explosion of checkpoint blockade inhibition studies" that initially made inroads in melanoma and non-small cell lung cancer, but is also gaining traction in bladder cancer.

Simple Urine Biomarker Test Could Identify Early-Stage Renal Cell Carcinoma

June 4th 2015

Two urine biomarkers, aquaporin 1 and perilipin 2, could be the key to the development of a simple urine test that leads to the detection of asymptomatic, early-stage kidney cancer.